Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$49.74 USD

49.74
6,764,645

+0.25 (0.51%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $49.74 0.00 (0.00%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?

by Zacks Equity Research

The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.

Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $49.49 in the latest trading session, marking a -1% move from the prior day.

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

by Zacks Equity Research

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

Alexandria Sells Asset to Redeploy in Development, Redevelopment Moves

by Zacks Equity Research

Keeping up with its capital-recycling strategy, Alexandria announces the completion of the sale of 1165 Eastlake Avenue East for $150 million.

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?

by Zacks Equity Research

Sector ETF report for RSPH

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $48.59, indicating a -1.4% shift from the previous trading day.

Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

by Zacks Equity Research

BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

by Zacks Equity Research

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.

Implied Volatility Surging for Bristol-Myers (BMY) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Bristol-Myers (BMY) stock based on the movements in the options market lately.

Argenx (ARGX) Moves 4.0% Higher: Will This Strength Last?

by Zacks Equity Research

Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Bristol Myers Squibb (BMY) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $49.80 in the latest trading session, marking a -0.32% move from the prior day.

Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEV

Bristol Myers Squibb (BMY) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $49.95 in the latest trading session, marking a +0.46% move from the prior day.

Exact Sciences (EXAS) Up 7.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

by Zacks Equity Research

Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.

Repligen (RGEN) Down 13.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for ONEV

Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for COWZ

Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for COWZ

Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review

by Zacks Equity Research

Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.

Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated

by Zacks Equity Research

Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.

Kymera (KYMR) to Raise $225 Million Through Offering of Shares

by Zacks Equity Research

Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.